Ipsen für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: A0ESMG / ISIN: FR0010259150

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Ipsen

27.07.23		Ipsen S.A. publishes its 2023 Half-Year Financial Report (GlobeNewswire)
27.07.23		Ipsen delivers solid H1 2023 results and upgrades its full-year guidance (GlobeNewswire)
25.07.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2023 (GlobeNewswire)
24.07.23		Ipsen announces a simplification of the concert of its principal shareholders representing 56.62% of the share capital and 72.36% of voting rights - effective from December 19, 2023 (GlobeNewswire)
21.07.23		Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome (GlobeNewswire)
19.07.23		Ipsen announces European Commission decision on palovarotene for the treatment of FOP (GlobeNewswire)
18.07.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2023 (GlobeNewswire)
11.07.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2023 (GlobeNewswire)
10.07.23		Ipsen – Half year statement – 2023 06 30 (GlobeNewswire)
10.07.23		Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
04.07.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2023 (GlobeNewswire)
30.06.23		Ipsen and GENFIT Announce Positive Results from Phase III ELATIVE trial of elafibranor in patients with primary biliary cholangitis, a rare cholestatic liver disease (GlobeNewswire)
29.06.23		Ipsen announces positive outcome of FDA Advisory Committee on investigational palovarotene for fibrodysplasia ossificans progressiva (GlobeNewswire)
27.06.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2023 (GlobeNewswire)
20.06.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2023 (GlobeNewswire)
14.06.23		Ipsen announces U.S. FDA submission acceptance of its supplemental New Drug Application for Onivyde regimen in first-line metastatic pancreatic ductal adenocarcinoma (GlobeNewswire)
13.06.23		U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome (GlobeNewswire)
13.06.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2023 (GlobeNewswire)
12.06.23		Ipsen to present new data on clinical outcomes and patient validation tools from growing rare liver disease portfolio at EASL 2023 (GlobeNewswire)
09.06.23		Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
06.06.23		IPSEN - Buy-back programme - Art 5 of MAR - Week 22 - 2023 (GlobeNewswire)
01.06.23		Ipsen SA initiates a share buy-back program to cover its free employee share-allocation plan (GlobeNewswire)
31.05.23		Ipsen S.A. - Combined Shareholders’ Meeting of Ipsen S.A. held on 31 May 2023 (GlobeNewswire)
31.05.23		Ipsen - Description of the regulatory framework of the share repurchase program to be approved at the Combined Shareholders’ Meeting on 31 May 2023 (GlobeNewswire)
26.05.23		Ipsen receives CHMP negative opinion, following re-examination of potential first FOP treatment in the E.U. (GlobeNewswire)
17.05.23		Ipsen to present new Bylvay® (odevixibat) data at annual ESPGHAN congress, showcasing commitment to furthering treatment for rare cholestatic liver diseases (GlobeNewswire)
10.05.23		Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital - April 2023 (GlobeNewswire)
10.05.23		Ipsen : 2023 CSM - Formalities for making available preparatory documents to the Meeting (GlobeNewswire)
27.04.23		Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance (GlobeNewswire)
24.04.23		Ipsen appoints Sandra Silvestri as EVP, Chief Medical Officer and Head of Global Medical Affairs, Patient Safety and Patient Affairs (GlobeNewswire)
11.04.23		Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
06.04.23		Ipsen S.A. publishes its 2022 Universal registration document (GlobeNewswire)
16.03.23		Ipsen receives new FDA PDUFA date for investigational palovarotene for the treatment of people with FOP (GlobeNewswire)
10.03.23		Ipsen SA - Monthly information relative to the total number of voting rights and shares composing the share capital (GlobeNewswire)
02.03.23		Ipsen completes acquisition of Albireo, expanding the scope of its Rare Disease portfolio (GlobeNewswire)
22.02.23		Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023 (GlobeNewswire)
15.02.23		Ipsen, Université de Montréal and IRICoR broaden existing oncology partnership, with an exclusive license agreement and two new discovery-stage programs (GlobeNewswire)
13.02.23		Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years’ follow-up in first-line advanced renal cell carcinoma (GlobeNewswire)
27.01.23		Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U. (Businesswire)
20.01.23		Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI (Businesswire)
09.01.23		Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases (Businesswire)
23.12.22		Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva (Businesswire)
09.11.22		Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (Businesswire)
27.10.22		Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance (Businesswire)
25.10.22		Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting (Businesswire)
12.08.22		Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology (Businesswire)
05.08.22		Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022 (Businesswire)
03.08.22		Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer (Businesswire)
01.08.22		Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic (Businesswire)
29.06.22		Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission (Businesswire)

Zurück | 1 | 2 | 3 | Weiter

Newssuche

Meistgelesene Nachrichten

Musk soll gehen: Tesla-Investor Ross Gerber plädiert für neuen CEO

Cathie Wood kauft wieder zu: NVIDIA-Aktien erneut im Fokus des ARK-ETFs

Zoll-Sorgen drücken Tesla-Aktie: Immer mehr Analysten werden skeptisch

Bitcoin Kurs Prognose: 100.000 US-Dollar oder Absturz?

Diese Aktien empfehlen Experten zu kaufen

Trumps Zollpause bringt Erleichterung - Analysten bleiben skeptisch

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2025 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	21.04.2025 04:41
Kaufwert:	EUR
	Hinzufügen Speichern

Ipsen Aktie

WKN: A0ESMG / ISIN: FR0010259150

Nachrichten zu Ipsen

Newssuche

Meistgelesene Nachrichten